- Home
- FCF vs ZLAB Comparison
FCF vs ZLAB Comparison
Compare FCF & ZLAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | FCF | ZLAB |
|---|---|---|
| Founded | 1934 | 2013 |
| Country | United States | China |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.9B | 1.8B |
| IPO Year | 1994 | 2017 |
Fundamental Metrics
Financial Performance| Metric | FCF | ZLAB |
|---|---|---|
| Price | $16.80 | $18.37 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 4 | 7 |
| Target Price | $19.75 | ★ $49.44 |
| AVG Volume (30 Days) | ★ 785.7K | 544.8K |
| Earning Date | 04-29-2026 | 05-29-2026 |
| Dividend Yield | ★ 3.21% | N/A |
| EPS Growth | 5.76 | ★ 38.46 |
| EPS | ★ 1.47 | N/A |
| Revenue | N/A | ★ $460,156,000.00 |
| Revenue This Year | $16.32 | $14.46 |
| Revenue Next Year | $6.25 | $29.47 |
| P/E Ratio | $11.43 | ★ N/A |
| Revenue Growth | N/A | ★ 15.33 |
| 52 Week Low | $13.54 | $15.96 |
| 52 Week High | $19.08 | $44.34 |
Technical Indicators
Market Signals| Indicator | FCF | ZLAB |
|---|---|---|
| Relative Strength Index (RSI) | 33.97 | 44.52 |
| Support Level | $16.26 | $16.77 |
| Resistance Level | $16.96 | $19.71 |
| Average True Range (ATR) | 0.42 | 0.76 |
| MACD | -0.14 | -0.11 |
| Stochastic Oscillator | 21.40 | 43.03 |
Price Performance
Historical ComparisonAbout FCF First Commonwealth Financial Corporation
First Commonwealth Financial Corp functions in the financial services sector in the United States. Through its subsidiary, it offers a range of consumer and commercial banking services such as personal checking accounts, interest-earning checking accounts, savings accounts, insured money market accounts, investment certificates, fixed & variable rate certificates of deposit, and various kinds of loans. It also provides trust and wealth management services and offers insurance products. The company earns the majority of its revenue through net interest income.
About ZLAB Zai Lab Limited
Zai Lab Ltd is a biopharmaceutical company focusing on discovering or licensing, developing, and commercializing proprietary therapeutics that address areas of unmet medical need including in the fields of oncology, autoimmune and infectious diseases. The pipeline of proprietary drug candidates of the company includes ZL-1218 (CCR8) Solid Tumors, ZL-1310 (DLL3 ADC) ES-SCLC Other NECs, ZL-6301 (ROR1 ADC) Solid Tumors, ZL 6201 (LRRC15 ADC) Solid Tumors.